Kornimate/medical-research-clean huggingface dataset:
milk proteins and micronutrient supplementation in obese children

Conditions: Obesity, Childhood

Summary: milk proteins and micronutrients could be beneficial in the prevention and treatment of obesity. the objective was to evaluate a supplement with milk proteins and multivitamins and minerals with nutrition education on anthropometry, body composition, micronutrient status, blood pressure, lipid profile, systemic inflammation, leptin and insulin resistance in obese children at baseline and after 6 months.

obese children were selected in elementary schools from 5 rural communities of the state of querétaro. one hundred fifty two obese children (z-score \>2 standard deviations) aged 6-11y were randomly assigned to receive one of two treatments: 1) 237ml/day of milk proteins and multiple micronutrients supplement (mpms) plus nutrition education (ne) program or 2) ne alone for 24 weeks. children in both groups were evaluated at baseline and 6 months after treatment initiated. at both times the following variables were evaluated: visit 1 (screening): mothers and parents received oral and written information regarding all aspects of the study. informed consent, medical history, demographic information, weight and height were obtained. visit 2 (clinical laboratory testing): a blood preasure and sample was taken by an specialist. blood test included glucose, total cholesterol, triglycerides, hdl cholesterol and ldl cholesterol, tumor necrosis factor alpha (tnf-α), interleukin-6 (il-6) and interleukin-10 (il-10), c reactive protein, insulin and leptin. visit 3 (nutrition clinic at uaq): body composition was determined by dexa. the ne were given at nutrition clinic and school to the children's parents each week.

Eligibility criteria:
inclusion criteria: * children with obesity (bmi\>30) * aged: 6 to 11 years * both sex * parents accepted to participate and signed informant consent exclusion criteria: * children with dyslipidemia * metabolic disease * hypertension * physical disability * using vitamins and minerals supplements and/or receiving treatment for obesity during the last 3 months.

Keywords: micronutrients obesity school-age children milk proteins
a norwegian observational trial evaluating the treatment of advanced renal cell cancer patients under treatment of afinitor

Conditions: Metastatic Renal Cell Carcinoma (mRCC)

Summary: this is a norwegian prospective registration, observational study of patients with advanced renal cell cancer on afinitor treatment after failure of one tyrosine kinase inhibitor (tki) ( e.g. sunitinib or sorafenib). the goal is to document the treatment algorithm of these patients in norway and the efficacy and tolerability of afinitor® in a pure 2.line setting.


Eligibility criteria:
inclusion criteria: * age \> 18 years * confirmed diagnosis of advanced renal cell cancer * progression on or after one vegf -tki (e.g. sunitibin, sorafenib) * written informed consent exclusion criteria: none other protocol-defined inclusion/exclusion criteria may apply

Keywords: mrcc, observational, afinitor, everolimus, 2.line
verify the performance in clinical practice of the immersive virtual reality platform grail (gait real-time analysis interactive lab)

Conditions: Acquired Brain Injury; Cerebral Palsy

Summary: gait pattern difficulties, balance and coordination deficits often characterize patients with congenital and acquired neuromotor disorders and have a significant impact on the quality of life of these subjects. there are various treatments used and in recent years, the advent of advanced technologies in rehabilitation and, in particular, devices based on virtual reality, has opened up new possibilities in rehabilitation. virtual reality is a promising strategy that incorporates many principles crucial to motor learning, such as high-intensity, repetitive, goal-oriented tasks, enhanced synchronized sensory signals, and active participation. the virtual environment is also suitable for personalized treatment based on the needs of the individual patient. the grail (gait real-time analysis interactive lab) is a device that integrates immersive virtual reality with an instrumented treadmill and a motion capture system, which can be used with both rehabilitation and evaluation goals. to date, there are still few studies of this device in the pediatric field. the objective of the study is to verify the performance in clinical practice of the immersive virtual reality platform grail and determine any secondary effects by evaluating whether they entail acceptable risks compared to the expected performances following the protocol defined at the irccs medea by bosisio parini, in children and adolescents with congenital and acquired neuromotor pathology. patients suffering from acquired and congenital brain injuries undergo a combined rehabilitation treatment consisting of 20 sessions with grail and 20 physiotherapy sessions in four weeks. the same subjects undergo evaluations before and at the end of the treatment the study is prospective and involves the verification of performance through clinical and instrumental evaluations in the population of subjects treated with the grail device at the irccs medea-bosisio parini.


Eligibility criteria:
inclusion criteria: * capable of following verbal requests * gross motor function classification system score i to iii exclusion criteria: * severe spasticity * severe cognitive disability * severe auditory or visual disability
biofields therapy on warts

Conditions: Wart; Energy Medecine; Magnetism

Summary: traditionally, healers are willing to look after, two out of three french citizens have already appealed to them at least once during their lives. many healers in good faith are exercising their magnetism as a "gift" often inherited from elders. now, they create interest of doctors who do not hesitate in some cases to ensure their cooperation, to implicitly recognize their mysterious talents. some serious studies have examined these practices: several studies have been conducted on the influence of biofield therapies in pain, depression and fatigue in cancer disease. the investigators propose a study of the effect of magnetism on the wart disease whose cure is objectively assessable. sixty-two subjects in total would be included, comparing 2 proportions observed: the proportion of healing in the group treated with a "real" biofield therapist (recognized and affiliated to the national group for alternative medicine in france) to the proportion of healing in the group treated with a "fake" biofield therapist (someone assessed as not having capacity to magnetize). the "fake" biofield therapist, placebo, has been trained to replicate gestures during a training validated by an independent recognized biofield therapist.


Eligibility criteria:
patients with common warts on hands or feet for over at least 3 months are eligible for the study. patients fulfilling one or more of the following criteria will not be included: lack of informed consent prior to randomization, younger than 18 years or under judicial protection, treated with oral corticotherapy for more than 6 months, immunosuppressed or with history of transplant surgery, undergoing chemotherapy or suspected to have carcinomatous warts, or patients with infected warts, injured warts or already treated within 90 days with chemical processing, medical device, surgery or ever treated with biofield therapy. subject will be excluded from the study if its warts was treated by other treatment during protocol. * ulcerated wart * cancerous wart
mapping human muscle satellite cell fate by real-time imaging

Conditions: Flaccid Muscle Tone

Summary: mapping human muscle satellite cell fate by real-time imaging

the aim of this study is to obtain human muscle samples for cell culturing to analyze muscle cell development in real-time to uncover factors that influence growth.

Eligibility criteria:
-inclusion criteria: * men 20-29 yrs * bmi between 20 and 34.9 * fasting glucose \<110 mg/dl * blood pressure \<160/100mm hg * non-diabetic * ldl-cholesterol \<160mg/dl * triacylglycerol \<400 mg/dl * makers of kidney, liver, and heart functions within 10% of clinical normalcy * \<1.5hr /wk of habitual aerobic exercise training and no resistance exercise training in the past 6 months exclusion criteria: * men \ 29 yrs * bmi between \ 34.9 * fasting glucose \>110 mg/dl * blood pressure \>160/100mm hg * non-diabetic * ldl-cholesterol \>160mg/dl * triacylglycerol \>400 mg/dl * pre-existing kidney or liver conditions --\>1.5hr /wk of habitual aerobic exercise training and no resistance exercise training in the past 6 months * currently taking prescribed blood thinners
effects of far infrared radiation on fibromyalgia patients

Conditions: Fibromyalgia

Summary: this study aimed to evaluate the effectiveness of infrared radiation in improving the various symptoms of fibromyalgia syndrome, by using a long-sleeved white shirt impregnated with a long-infrared irradiating bioceramic, as well as the adherence to it and its applicability in daily routines. a prospective, experimental, randomized, and double-blind study was carried. the study was implemented over 7 months, with a total of 5 visits for each patient. participants were randomly allocated in experimental or control group. those included in the experimental group received a shirt impregnated with ceramic emitting long infrared waves while participants in the placebo group received an exactly looking shirt, but not impregnated with ceramic emitting long infrared waves. each visit comprised clinical evaluation and self-report scales filling (wps, ss and fiqr scales).


Eligibility criteria:
inclusion criteria: * age superior to 18 years-old * ability to freely sign the informed consent form * generalized pain index scores (wpi ≥ 7 and ss score ≥ 5, or wpi ≥ 3 and ≤ 6 with ss ≥ 9, presence of abdominal pain and / or with depression and / or headache, in the last 6 months, at the screening consultation). exclusion criteria: * dermatological diseases * other rheumatic and /or autoimmune diseases
medibeat - heartbeat observation trial

Conditions: Low Blood Pressure; Blood Pressure; High Blood Pressure; Hypertension; Hypotension

Summary: the goal of the study was to compare the current gold standard blood pressure instrument (a mercury-filled sphygmomanometer with cuff and stethoscope) with the new experimental algorithm developed by heartbeat technologies ltd. to that end, participants were recruited from markham, ontario and participated in a series of alternating blood pressure measurements over a period of 45 minutes. comparisons were made between manual measurements and device measurements to determine the quality of the device readings. measurements were taken by trained nurses and staff were consistent across the study duration.

the gold standard instrument for blood pressure measurement is a mercury-filled sphygmomanometer with cuff and stethoscope (canadian agency for drugs and technologies in health; canadian electronic library, 2012). however, such a device is not the most convenient for client self-monitoring or virtual (remote) care. thus, there is a desire for an accurate, reliable alternative for the traditional mercury-containing sphygmomanometer. heartbeat technologies ltd. ("heartbeat") has developed a novel approach to measuring blood pressure after an initial blood pressure reading using the conventional measurement method, supplemented by specific characteristics of a person (age, gender, height, weight, and heart rate), has established a "baseline measurement" for the person. the "novel approach" uses a finger pulse oximeter, the contec cms50ew device (figure 1) (manufactured by contec medical systems co., ltd., shanghai, people's republic of china). the finger pulse oximeter detects the changes in blood volume directly below the person's skin and indirectly measures oxygen saturation in the blood. the measurement is in the form of a photoplethysmogram (ppg) which is captured by the contec oximeter and then, by bluetooth technology, transmitted to a smartphone or tablet. a heartbeat application, called medibeat, on the smartphone or tablet then transmits the ppg to a server where a proprietary algorithm analyzes the baseline measurement for the person and the ppg to calculate the person's current blood pressure. heartbeat's intent is that the current blood pressure reading would then be made available to both the client and the health provider through separate web-based interfaces. providers would be able to log onto the heartbeat web-based application from anywhere to review and monitor the blood pressure of multiple clients, while clients can log onto the application to track their own measurements.

Eligibility criteria:
inclusion criteria: * adult over 25 years of age exclusion criteria: * those who have heart arrhythmias, * atrial fibrillations or atrial flutters, * an inaudible korotkoff sound, * wounds of the upper arms/wrists, missing fingers, and/or * an arm circumference of more than 55 cm will be excluded
interferon α2a versus cyclosporine for refractory behçet's disease uveitis

Conditions: Behçet Disease; Uveitis

Summary: brief summary: this study compares the long-term efficacy and safety of interferon (ifn) α2a and cyclosporine (cyclosporin a, csa) following suppression of acute attack by high-dose oral glucocorticosteroid in patients with refractory behçet's uveitis (bdu). half of the participants will receive ifnα2a while the other half will receive csa.

detailed description: both csa and ifnα2a have been shown to be effective for long-term control of bdu, however, randomized prospective comparative studies are scarce, particularly in east asian populations. our preliminary data gave us the impression that ifnα2a might be more effectiveness than csa in long-term control of refractory bdu, and this study aimed to compare their effectiveness and safety profiles in a well-designed prospective study. refractory bdu is defined as relapse of posterior or pan- uveitis with at least 10mg daily prednisone (or equivalent) and one traditional immunomodulatory treatment (imt) agents. the acute attack is controlled with large dose oral corticosteroid (60mg daily prednisone) for 4 weeks, and then the patients are randomly assigned to the ifn arm and the csa arm, in which patients are treated with ifnα2a (3×10\^6 iu qd for 4 weeks and qod thereafter) and csa (100mg bid), respectively, along with a fixed tapering regimen of corticosteroid. patients were followed up until relapse, or for 12 months.

Eligibility criteria:
inclusion criteria: * refractory bdu patients fulfilling the international criteria for behçet's disease (icbd) published in 2013 with recent recurrence of pan- or posterior uveitis; * the patient should be on ≥10mg/d oral prednisone or equivalent with at least one of the following imt agents: cyclophosphamide≥50mg/d, csa≥100mg/d, azathioprine≥50mg/d, methotrexate≥15mg/w, mycophenolate≥1000mg/d, tacrolimus≥2mg/d. exclusion criteria: * previous treatment with interferon-α; * pregnancy, breast feeding women; * malignancy; * renal impairment (creatinine \> 1.5 mg/dl); * uncontrolled hypertension or diabetes; * depression or other psychic disorders; * history of acute or chronic inflammatory joint or autoimmune disease; * patients with severe extra-ocular involvement other than oral/genital ulcer and skin involvement; * organ or bone marrow transplant recipient, cardiac failure \> nyha iii; * acute liver disease with alt or sgpt 2x above normal; * white blood cell count \< 3500/mm\^3; * platelet count \< 100000/mm\^3; * hgb \< 8.5g/dl; * t-spot tb: ≥200 sfcs per 10\^6 pbmc; * active peptic ulcer, systemic or local infection, moderate to severe osteoporosis or other contraindications of large dose corticosteroids; * previous intolerance to csa; * other severe ocular diseases or intraocular surgery within 3 months; * media opacity precluding a clear view of the fundus; * positive screen test for hbv, hcv, hiv infection or syphilis; * body weight \<45 kg; * alcohol abuse or drug abuse; * mental impairment; * uncooperative attitude.

Keywords: effectiveness, safety
synaptic plasticity in the epicardial ganglionated plexi

Conditions: Atrial Fibrillation

Summary: atrial fibrillation (af) is the most common arrhythmia and the prevalence increase with age. autonomic nervous system play a critical role in the initiation and maintenance of af. the intrinsic cardiac autonomic nervous system includes ganglionated plexus (gp) modulate the level of parasympathetic activity to the heart. experimental and clinical studies suggest that gp activation plays a significant role in clinical af in both the initiation of and the maintenance of af. synaptic plasticity is defined as the ability of synapses to change their strength of transmission. plasticity of synaptic connections in the brain is a major focus of neuroscience research, as it is the primary mechanism underpinning learning and memory. beyond the brain however, plasticity in peripheral neurons is less well understood, particularly in the gp neurons innervating the heart. the ability of these neurons to alter parasympathetic activity suggests that plasticity may indeed occur at the synapses formed on and by gp neurons. such changes may not only fine-tune autonomic innervation of the heart, but could also be a source of maladaptive plasticity during atrial fibrillation. low level tragus stimulation (llts) has been shown to decrease af burden among patients with paroxysmal af. however, the exact mechanism remains unclear. the objective of this study is to examine changes in synaptic density of gp neurons in patients with paroxysmal af and persistent af compared to those without af undergoing cardiac surgery. in addition, we aim to examine the effect of llts on the synaptic plasticity of the gp neurons. a group of patients undergoing open heart surgery will be randomized to active llts for 30 min (pulse width of 200 μs, amplitude of 20 ma and a pulse frequency of 20 hz) or no stimulation. biopsy from gp tissue will be taken immediately after stimulation and histological staining for choline acetyl transferase (chat), tyrosine hydroxylase (th) and synaptophysin will be performed to examine synaptic plasticity. understanding the effect of llts on gp sp will help to determine whether changes in synaptic plasticity can increase or decrease autonomic tone of the heart, and its role in generating the aberrant electrical impulses in the gp around the pulmonary veins that can trigger and drive af.


Eligibility criteria:
inclusion criteria: 1. male and female patients older than 21 year old 2. patient is going to have open heart surgery. exclusion criteria: 1. patients undergoing emergent open heart surgery.
letrozole and misoprostol for early pregnancy loss management

Conditions: Early Pregnancy Loss; Miscarriage in First Trimester; Miscarriage

Summary: a pilot cohort study to preliminarily investigate the efficacy of pretreatment with letrozole 10 mg daily for three consecutive days followed by treatment with misoprostol 800 mcg vaginally for medical management of early pregnancy loss in a us population. patients will be followed to assess efficacy of this treatment regimen, as well as additional interventions needed, side effects, adverse events, and patient acceptability.


Eligibility criteria:
inclusion criteria: * able to participate in the informed consent process and provide a signed and dated consent form * stated willingness to comply with all study procedures and availability for the duration of the study * access to working mobile phone * english-speaking * age 18 years or older * confirmed diagnosis of intrauterine embryonic/fetal demise or anembryonic gestation (ultrasound examination demonstrates a fetal pole without cardiac activity measuring between 5.3 and 40 mm or an abnormal growth pattern diagnostic of early pregnancy failure) exclusion criteria: * incomplete or inevitable abortion * contraindication of allergy to letrozole or misoprostol * unable to return for clinic-based follow-up * twin or multiple pregnancy
added value of gadoxetic acid-enhanced liver mri

Conditions: Hcc; Diagnosis

Summary: it would be valuable to evaluate whether gadoxetic acid-enhanced liver mri would provide additional value for characterizing atypical or small (1\~2cm) hepatic nodules at ct and to reduce the necessity of biopsy in patients with high risk of hcc. therefore, the purpose of this study is to evaluate added value of gadoxetic acid-enhanced mri for diagnosis of hcc in patients with small (10-19mm) or atypical hepatic nodules at ct.

in terms of confirmative diagnosis, hcc is unique compared with other malignant tumors, as it can be diagnosed noninvasively based on its characteristic imaging features, that is, arterial hyperenhancement (washin) and hypoenhancement (washout) on portal or delayed phase at contrast-enhanced computed tomography (ct) or magnetic resonance imaging (mri) using extracellular contrast media (eccm). according to liver imaging reporting and data system (li-rads), hypointensity and isointensity on hepatobiliary phase (hbp) at gadoxetic acid-enhanced mri are suggestive of malignancy and benignity, respectively, and those features are uniquely provided by only hepatocyte-specific contrast agent. however, these features are not included in diagnostic criteria because of its non-specificity, and indeed, gadoxetic acid-enhanced mri is not yet included in aasld and easl guidelines as a diagnostic modality. if gadoxetic acid-enhanced mri would provide better performance to diagnose hcc than ct, gadoxetic acid-enhanced mri should be considered as a next step before biopsy in those small and/or atypical nodules to avoid potential diagnostic pitfall and morbidity, which is currently depending on physicians' decision. thus, it would be valuable to evaluate whether gadoxetic acid-enhanced liver mri would provide additional value for characterizing atypical or small (1\~2cm) hepatic nodules at ct and to reduce the necessity of biopsy in patients with high risk of hcc. therefore, the purpose of this study is to evaluate added value of gadoxetic acid-enhanced mri for diagnosis of hcc in patients with small (10-19mm) or atypical hepatic nodules at ct.

Eligibility criteria:
inclusion criteria: * patients with chronic hepatitis b or cirrhosis of any etiology * signed informed consent and * being referred to radiology department for gadoxetic acid-enhanced mri due to small nodule (10-19mm) at contrast-enhanced ct scan within 30 days as an radiofrequency ablation (rfa) work-up or * being referred to radiology department for percutaneous biopsy for atypical hepatic nodules (≥20mm) detected at contrast-enhanced ct within 30 days before biopsy exclusion criteria: * any contraindication for mri and mr contrast agent

Keywords: mri gadoxetic acid ct